Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.

Inclusion Criteria:Incurable, progressing and/or life-threatening cancerExpected residual survival of at least 3 monthsNo efficient remaining standard treatment optionsPatient recruited from the Region of Northern Jutland, DenmarkExclusion Criteria:WHO Performance Status >2Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment